Antipodes Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Antipodes Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.7K	Hold	127	–	–	﹤0.01%	105
2025 Q4	$57.6K	Buy	+127	New	+$54.7K	﹤0.01%	103
2025 Q3	–	Sell	-241	Closed	-$107K	–	137
2025 Q2	$107K	Sell	241 -14	-5%	-$6.45K	﹤0.01%	73
2025 Q1	$124K	Buy	+255	New	+$119K	﹤0.01%	68
2024 Q4	–	Sell	-127,853	Closed	-$59.5M	–	95
2024 Q3	$59.5M	Buy	127,853 +558	+0.4%	+$268K	2.06%	22
2024 Q2	$59.7M	Sell	127,295 -62,105	-33%	-$27M	2.17%	21
2024 Q1	$78.2M	Buy	189,400 +100,480	+113%	+$42.5M	2.47%	19
2023 Q4	$36.2M	Buy	+88,920	New	+$32.8M	1.13%	29

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Antipodes Partners's VRTX Position: Q1 2026 in Review

Antipodes Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 127 shares worth $56.7K. The position accounts for ﹤0.01% of the portfolio, ranked #105.

Antipodes Partners first reported a position in VRTX in Q4 2023 and has held it in 8 quarters since. The position peaked at $78.2M in Q1 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Antipodes Partners held 127 shares of Vertex Pharmaceuticals worth $56.7K as of Q1 2026.
Antipodes Partners left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Antipodes Partners's portfolio in Q1 2026, its #105 holding.
Antipodes Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
Antipodes Partners's Vertex Pharmaceuticals position peaked at $78.2M in Q1 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.